NDA for Low-Dose Fenfluramine Submitted for Treatment of Dravet Syndrome
Zogenix announced the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Fintepla (low-dose fenfluramine; ZX008) oral solution for the treatment of seizures associated with Dravet syndrome.
